NAC: a small molecule with wide-reaching benefits

N-acetylcysteine, better known as NAC, is a form of the amino acid cysteine. It has been used in medicine for decades as a treatment for paracetamol overdose and as a mucolytic to help clear thick respiratory secretions. Increasingly, however, NAC is being recognised for its wider role in antioxidant defence, respiratory health and cellular resilience.

One of NAC’s most important roles is supplying cysteine for the production of glutathione, one of the body’s principal intracellular antioxidants. Glutathione helps neutralise reactive oxygen species, protect cellular structures and maintain the delicate balance between oxidation and reduction within the body.

NAC also possesses a sulphur-containing thiol group, written chemically as –SH. This allows it to participate directly in redox reactions and helps explain both its antioxidant and mucus-thinning properties. Rather than acting as a simple standalone antioxidant, NAC supports the body’s own antioxidant network by restoring the building blocks needed to make glutathione. 

Respiratory mucus contains large proteins called mucins, which are linked together by disulphide bonds. These molecular bridges contribute to the thickness and elasticity of mucus.

The free thiol group in NAC can disrupt or rearrange these disulphide bonds. This makes mucus less thick and sticky, allowing it to be cleared more easily through coughing and the normal movement of tiny hair-like structures called cilia. This may be particularly useful when a cold or respiratory infection produces a congested, productive cough. 

It is important to clarify that disulphide bonds are not themselves antioxidants. NAC’s antioxidant action comes from its redox-active thiol group and its ability to replenish glutathione, while its interaction with disulphide bonds explains its mucolytic action.

NAC is not a cure for colds or influenza, and the evidence for routinely using it to prevent uncomplicated seasonal infections remains limited. Its potential value lies in supporting the environment in which recovery takes place.

Unlike medicines that simply lower temperature, reduce pain or constrict nasal blood vessels, NAC works primarily by supporting antioxidant capacity and helping the respiratory system clear secretions. It may therefore be particularly relevant when thick mucus, chest congestion or a productive cough are prominent symptoms.

This does not make NAC a direct replacement for paracetamol or a decongestant. These medicines perform different jobs.  NAC offers a more supportive role by working with mucus clearance rather than simply masking discomfort.

Oral NAC generally has a favourable safety profile. Reviews of respiratory studies have found NAC to be well tolerated across a range of doses, although taking more does not necessarily produce a greater benefit.

Anyone with asthma, a history of stomach ulcers or a bleeding disorder should seek individual advice before taking NAC. It may also interact with certain medicines, including nitrate treatments used for angina. Advice from a pharmacist or clinician is sensible during pregnancy or breastfeeding, before giving NAC to a child, or when taking regular medication.

NAC is more than a conventional antioxidant supplement. By supplying cysteine for glutathione production and using its thiol group to interact with disulphide bonds in mucus, it supports two important processes at once: cellular antioxidant defence and respiratory clearance.

The strongest evidence supports its established mucolytic use and its role in specific respiratory conditions. Its benefits for general health is best regarded as a potentially useful support rather than a cure-all. Used appropriately, NAC offers a practical example of supporting the body’s own protective systems instead of merely silencing symptoms.

1. Barne M, et al. N-acetylcysteine: evidence-based consensus document on the therapeutic advantages in respiratory diseases. Frontiers in Medicine. 2026;13:1810363. [frontiersin.org], [pmc.ncbi.nlm.nih.gov]
2. Mokra D, et al. Advances in the use of N-acetylcysteine in chronic respiratory diseases. Antioxidants. 2023;12(9):1713. [mdpi.com]
3. Calverley P, Rogliani P, Papi A. Safety of N-acetylcysteine at high doses in chronic respiratory diseases: a review. Drug Safety. 2021;44:273–290. [pmc.ncbi.nlm.nih.gov], [link.springer.com]